Cancer Research KI Scientific Advisory Board
|
|
|
|
|
A common Scientific Advisory Board (SAB) for Cancer Research KI and the Comprehensive Cancer Center (CCC) at the Karolinska has been formally established.
The board of directors of the CCC, aimed to incorporate advisory members with broad expertise in clinical, basic and caring cancer research; covering a varied set of cancer subdisciplines.
This common SAB will be able to advise on matters including, but not limited to, the long-term strategic development of research, education, care and prevention within cancer for both Cancer Research KI and the CCC.
|
|
|
|
More information about the members can be found here.
|
|
|
|
Cancer Researcher Portrait
by Cancer Research KI
|
|
|
|
|
|
"Pick the supervisor and not the project"
|
|
Continuing strong with our virtual interviews we sat down with Johanna Ungerstedt, to discuss the intricacies of combining a clinical appointment with a research group and a family, as well as her journey of finding the right mentors.
.
|
|
Johanna Ungerstedt
Associate Professor, Specialist in Haematology and Internal Medicine
Dept. of Medicine Huddinge
|
|
|
|
|
“The competitive and strong-willed nature of Johanna Ungerstedt was shown very early on in her life. In fact by the time she was at ‘gymnasium’ (last three years of school here in Sweden, age 16-19) she was a member of the junior national team for bridge playing and already a National and Nordic Bridge Champion- as she puts it: “it was me and roughly 500 boys!”. What an opening statement, one that we (Cancer Research KI) could not have expected, so of course there were a lot of follow-up questions! It became clear from our conversation that Johanna enjoys being challenged and has no issues with some ‘friendly’ competition. Sadly, however, we also learnt that her best friend passed away from cancer during that time-frame. As she was already contemplating a move into medical school it became quite clear to her that the next challenge she wanted to face was that of medical school coupled to research. Her journey started when she was accepted onto the KI Summer School programme.."
|
|
Read the full interview with Johanna Ungerstedt on our home page.
Read more about Ungerstedt's research here.
|
|
|
|
Comprehensive Cancer Centre (CCC)
|
|
The Karolinska Institutet and the Karolinska University hospital received formal certification from the Organisation of European cancer institutes (OECIs) in March 2020 providing accreditation as a Comprehensive Cancer Center (CCC). As a result of this a Board of Directors (BoD) has been inducted representing KI and KUH. The assignment of the BoD is to lead the long-term strategic development of research, education, care and prevention within cancer in alignment with OECIs aims for a CCC. The BoD will formally respond to OECI and its General Assembly, as well as commence the planning of its first common annual report for the Karolinska CCC. The first task of the BoD was to appoint the international SAB.
BoD members include:
|
|
|
|
|
Jonas Bergh,
Prof. of Oncology, Director of Cancer Research KI @ KI
Patrik Rossi, Managing Director of the Cancer Theme @ KUH
|
|
|
Anna Martling,
Prof. of Surgey and Dean @ KI
Stephan Mielke,
Prof. of Hematology & Cellular Therapy, Scientific Director of the Cancer Centre
|
|
|
Martin O. Bergö,
Prof. of Molecular Medicine @ KI
Yvonne Wengström, Prof. and Director of Nursing Development @ KUH
|
|
|
Janne Lehtiö,
Prof. in Proteomics and Scientific Director at SciLifeLab
Eva Gustafsson, Head of care unit radiotherapy and BoD coordinator
|
|
|
|
The Personalised/ Precision Cancer Medicine (PCM) Program
|
|
In 2015 the PCM program was initiated to establish Personalized/Precision Cancer Medicine (PCM) as a leading treatment concept within academic cancer healthcare in Stockholm. The goal is to strengthen the infrastructure for local, national and international team science addressing PCM- in doing so, enhance the collaboration between scientists from KI, SciLifeLab along with clinicians at KUH. The program is sponsored by Radiumhemmets Research Funds (Radiumhemmets Forskningsfonder), in addition to some funding from Big Pharma and EU-programs. With the support from the president of KI, the director of KUH and that of SciLifeLab the PCM is a part of ‘Working Group 4’ of Cancer Research KI and acts as the Stockholm hub of Cancer Core Europe.
|
|
|
|
|
|
|
Core team of the program:
Claes Karlsson (Director, Oncologist), Michele Masucci (Project leader) and Ingemar Ernberg (Professor, Chairperson).
For enquiries please email: ingemar.ernberg@ki.se
Photo: Håkan Flank
|
|
|
|
|
Action Points of the PCM
| • | Enhance the local machinery for early clinical trials (phase 0-II). | | • | Stimulate innovative translational research for improved PCM. | | • | Streamline the utilization of infrastructures for -omics and other molecular tools, incl imaging technologies for PCM-research and diagnostics. |
|
|
| • | Support the development of bioinformatics support, data-sharing and clinical decision tools. | | • | Involve patient representatives and utilize patient self-reported datato optimize the collaboration with Cancer Core Europe (CCE). |
|
|
|
|
|
M4R program is aimed for researchers who are interested in learning more about the commercialization or implementation of research and collaborating with the business community. KI Innovations AB will run a mentorship program for cancer, stem cells and regenerative medicine researchers at KI in collaboration with Cancer Research KI and StratRegen.
For information and registration click here. Deadline: 1 October 2020
|
|
|
|
|
Task Forces for Different Diagnoses (TDD)
|
|
Cancer Research KI invites applications for support to Task Forces focusing on Specific Cancers. Established or new constellations can apply for 50 – 150.000 SEK in order to fund Task Force activities. Up to ten applications will be funded. The aim of the initiative is to encourage KI- and University Hospital-based researchers to join forces around one major group of cancers.
The Task Forces are intended to combine the expertise of basic researchers, clinicians, nursing and epidemiology researchers in order to solve interdisciplinary problems around a particular diagnosis. A Task Force may include groups already conducting research on the cancer type in question, as well as researchers interested in a general cancer problem who would like to find partners working on a specific group of cancers, e.g. focusing on different biological processes, technologies or therapeutic interventions with high relevance for cancer biology and the clinic.
Cancer Research KI support may be used for planning activities, joint workshops and as seed money to elaborate larger, interdisciplinary applications.
|
|
Further information available here.
Deadline: 30 September 2020
|
|
|
|
Global Academic Programs (GAP) Conference
|
|
|
|
|
|
|
This 3-day VIRTUAL conference is a forum where MD Anderson Cancer Center and its global network of hospitals, health systems and research institutions collaborate to develop impactful, innovative ideas and research that help MD Anderson achieve its mission. To register click here.
Dates: 17 -19 November 2020
|
|
|
|
Recent Research Publications
|
| • | Helin Vakifahmetoglu-Norberg (Dept. of Physiology and Pharmacology) Article |
Systematic analysis reveals a functional role for STAMBPL1 in the Epithelial-Mesenchymal Transition process across multiple carcinomas. Br. J. Cancer. (2020)
| • | Katja Petzold (Dept. of Medical Biochemistry and Biophysics) Article |
Base-pair conformational switch modulates miR-34a targeting of Sirt1 mRNA. Nature. (2020)
| • | Tanja Lövgren (Dept. of Oncology and Pathology) Article |
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. OncoImmunology. (2020); 9(1): 1792058.
| • | Fredrik Strand (Dept. of Oncology and Pathology and Breast Radiology at KUH) Article |
External evaluation of three commercial artificial intelligence algorithms for independent assessment of screening mammograms. JAMA Oncology. (2020)
| • | Hildur Helgadottir (Dept. of Oncology and Pathology) Article |
Multiple primary melanoma incidence trends over five decades, a nationwide population-based study. J. Natl. Cancer. Inst. (2020); djaa088.
| • | David Tamborero (Dept. of Oncology and Pathology) Article |
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat. Med. (2020); 26(7):992-994.
| • | Jonas F Ludvigsson (Dept. of Medical Epidemiology and Biostatistics) Article |
Risk of Small Bowel Adenocarcinoma, Adenomas, and Carcinoids in a Nationwide Cohort of Individuals With Celiac Disease. Gastroenterology. (2020); S0016-5085(20)34927-1.
| • | Susanna C Larsson (Inst. of Environmental Medicine) Article |
Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. (2020); 17(7):e1003178.
| • | Veronica Jackson and Ulrik Sartipy (Dept. of Molecular Medicine and Dept. of Surgery and Cardiothoracic Surgery) Article |
Household disposable income and long-term survival after pulmonary resections for lung cancer. Thorax. (2020); 75(9):764-770.
| • | Anna Falk and Margareta Wilhelm (Dept. of Neuroscience and Dept. of Microbiology, Tumor and Cell biology) Article |
Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc. Natl. Acad. Sci. U S A. (2020); 117(33):20127-20138.
|
|
|
|
|
Please send us your open positions for Master projects, PhD candidates and postdocs so that we can advertise them to our Cancer Research KI community.
|
|
|
|
|
|
|
|
Cancer Research KI is an overarching umbrella organisation and single point of entry to cancer research at Karolinska Institutet, conducted by some 250 research groups at multiple campuses and departments. The aim is to combine cancer research with clinical oncology by bringing together top level cancer scientists from different disciplines, with the overall goal to generate new scientific discoveries that can be rapidly translated into clinical practice for the benefit of patients and society.
|
|
|
|
|
|
|
